查看購物車
  • English
封面
市場調查報告書
商品編碼
1901604

肺癌基因組檢測市場－全球產業規模、佔有率、趨勢、機會和預測，按組件、技術、檢測板類型、樣本類型、最終用戶、地區和競爭格局分類，2021-2031年預測

Lung Cancer Genomic Testing Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Component, By Technology, By Panel Type, By Sample Type, By End User, By Region & Competition, 2021-2031F
出版日期: | 出版商: TechSci Research | 英文 183 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

全球肺癌基因組檢測市場規模將從2025年的21.7億美元成長到2031年的37.6億美元，複合年成長率達9.59%。肺癌基因組檢測涉及對腫瘤組織或液體活體組織切片樣本進行分子分析，以識別特定的基因改變，例如EGFR突變或ALK重排，這些變化決定了標靶治療方案的選擇。推動市場成長的主要因素是臨床向個人化醫療的轉型以及伴隨診斷對新型腫瘤藥物上市許可的嚴格監管要求。

市場概覽
預測期 2027-2031
市場規模：2025年 21.7億美元
市場規模：2031年 37.6億美元
複合年成長率：2026-2031年 9.59%
成長最快的細分市場 聚合酶鍊式反應
最大的市場 北美洲

主要市場促進因素

全球肺癌發生率和盛行率的不斷上升是基因組檢測市場發展的根本驅動力，不斷擴大的患者群體對精準分子診斷的需求日益成長。由於全球肺癌負擔依然沉重，醫療系統正日益要求所有新確診患者進行全面的生物標記檢測，以確定最有效的治療策略。

主要市場挑戰

下一代定序的報銷政策不統一，是限制全球肺癌基因組檢測市場成長的一大障礙。儘管臨床指引日益建議進行全面的基因組分析，但缺乏統一的支付方覆蓋範圍造成了嚴重的經濟摩擦，導致臨床應用與病患可及性脫節。

主要市場趨勢

從單基因檢測到全面的下一代定序 (NGS) 檢測，正在重塑肺癌的診斷標準。這項轉變的驅動力在於，需要從有限的組織樣本中有效地辨識多種可操作的基因改變。臨床醫生正逐漸放棄反覆的單生物標記檢測（這種檢測方式容易導致組織樣本耗竭），轉而採用廣泛的基因組分析，以便在單一流程中捕獲共存突變和複雜的特徵，例如腫瘤突變負荷。

目錄

第1章：產品概述

第2章：研究方法

第3章：執行概要

第4章：顧客之聲

第5章：全球肺癌基因組檢測市場展望

  • 市場規模及預測
    • 按價值
  • 市佔率及預測
    • 按組成部分（產品與服務）
    • 依技術分類（次世代定序、聚合酶鍊式反應、螢光原位雜合技術（FISH）/原位雜合技術（ISH）、其他）
    • 依檢測類型（單基因檢測與多基因檢測）
    • 依樣本類型（組織活體組織切片與液體活體組織切片）
    • 按最終用戶分類（學術和研究機構、醫院和診所、診斷實驗室、其他）
    • 按地區
    • 按公司（2025 年）
  • 市場地圖

第6章：北美肺癌基因組檢測市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 北美洲：國家分析
    • 美國
    • 加拿大
    • 墨西哥

第7章：歐洲肺癌基因組檢測市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 歐洲：國家分析
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙

第8章：亞太地區肺癌基因組檢測市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 亞太地區：國家分析
    • 中國
    • 印度
    • 日本
    • 韓國
    • 澳洲

第9章：中東和非洲肺癌基因組檢測市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 中東和非洲：國家分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非

第10章：南美洲肺癌基因組檢測市場展望

  • 市場規模及預測
  • 市佔率及預測
  • 南美洲：國家分析
    • 巴西
    • 哥倫比亞
    • 阿根廷

第11章：市場動態

  • 促進要素
  • 挑戰

第12章：市場趨勢與發展

  • 併購
  • 產品發布
  • 最新進展

第13章：全球肺癌基因組檢測市場：SWOT分析

第14章：波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商議價能力
  • 顧客的力量
  • 替代產品的威脅

第15章：競爭格局

  • QIAGEN NV
  • Agilent Technologies Inc.
  • Thermo Fisher Scientific Inc.
  • Quest Diagnostics Incorporated
  • Laboratory Corporation of America Holdings
  • CENTOGENE NV
  • BGI Genomics Co. Ltd.
  • CeGaT GmbH
  • Illumina Inc.
  • F. Hoffmann-La Roche Ltd

第16章：策略建議

第17章調查會社について,免責事項

簡介目錄
Product Code: 12818

The Global Lung Cancer Genomic Testing Market will grow from USD 2.17 Billion in 2025 to USD 3.76 Billion by 2031 at a 9.59% CAGR. Lung cancer genomic testing involves the molecular analysis of tumor tissue or liquid biopsies to identify specific genetic alterations such as EGFR mutations or ALK rearrangements that dictate the selection of targeted therapies. The market is primarily propelled by the clinical transition toward personalized medicine and the stringent regulatory requirement for companion diagnostics to authorize the use of novel oncology drugs.

Market Overview
Forecast Period2027-2031
Market Size 2025USD 2.17 Billion
Market Size 2031USD 3.76 Billion
CAGR 2026-20319.59%
Fastest Growing SegmentPolymerase Chain Reaction
Largest MarketNorth America

Key Market Drivers

The Rising Global Incidence and Prevalence of Lung Cancer serves as the foundational catalyst for the genomic testing market, creating an expanding patient pool that necessitates precise molecular diagnosis. As the burden of lung malignancy remains high globally, healthcare systems are increasingly mandating comprehensive biomarker testing for all newly diagnosed patients to determine the most effective management strategies. This volume-driven demand is evidenced by the sheer scale of diagnoses in major markets.

Key Market Challenges

The inconsistent reimbursement landscape for next-generation sequencing constitutes a substantial barrier hampering the growth of the Global Lung Cancer Genomic Testing Market. While clinical guidelines increasingly recommend comprehensive profiling, the lack of uniform payer coverage creates severe economic friction that disconnects clinical availability from patient accessibility. Diagnostic developers face restricted revenue potential as healthcare providers often hesitate to order advanced genomic profiling due to uncertainty regarding payment authorization.

Key Market Trends

The transition from single-gene assays to comprehensive next-generation sequencing (NGS) panels is reshaping the diagnostic standard for lung malignancy, driven by the need to efficiently identify multiple actionable alterations from limited tissue samples. Clinicians are increasingly abandoning iterative single-biomarker testing, which risks tissue exhaustion, in favor of broad genomic profiling that captures co-occurring mutations and complex signatures like tumor mutational burden in a single workflow. This consolidation is critical for matching patients to the growing array of targeted therapies without the latency of sequential testing.

Key Market Players

  • QIAGEN NV
  • Agilent Technologies Inc.
  • Thermo Fisher Scientific Inc.
  • Quest Diagnostics Incorporated
  • Laboratory Corporation of America Holdings
  • CENTOGENE N.V.
  • BGI Genomics Co. Ltd.
  • CeGaT GmbH
  • Illumina Inc.
  • F. Hoffmann-La Roche Ltd

Report Scope:

In this report, the Global Lung Cancer Genomic Testing Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

Lung Cancer Genomic Testing Market, By Component:

  • Products v/s Services

Lung Cancer Genomic Testing Market, By Technology:

  • Next Generation Sequencing
  • Polymerase Chain Reactions
  • Fluorescence In Situ Hybridization (FISH)/In Situ Hybridization (ISH)
  • Others

Lung Cancer Genomic Testing Market, By Panel Type:

  • Single Panel v/s Multi-Gene Panel

Lung Cancer Genomic Testing Market, By Sample Type:

  • Tissue Biopsy v/s Liquid Biopsy

Lung Cancer Genomic Testing Market, By End User:

  • Academic & Research Institutions
  • Hospitals & Clinics
  • Diagnostic Laboratories
  • Others

Lung Cancer Genomic Testing Market, By Region:

  • North America
  • United States
  • Canada
  • Mexico
  • Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
  • Asia Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
  • South America
  • Brazil
  • Argentina
  • Colombia
  • Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global Lung Cancer Genomic Testing Market.

Available Customizations:

Global Lung Cancer Genomic Testing Market report with the given market data, TechSci Research offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

  • Detailed analysis and profiling of additional market players (up to five).

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Lung Cancer Genomic Testing Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Component (Products v/s Services)
    • 5.2.2. By Technology (Next Generation Sequencing, Polymerase Chain Reactions, Fluorescence In Situ Hybridization (FISH)/In Situ Hybridization (ISH), Others)
    • 5.2.3. By Panel Type (Single Panel v/s Multi-Gene Panel)
    • 5.2.4. By Sample Type (Tissue Biopsy v/s Liquid Biopsy)
    • 5.2.5. By End User (Academic & Research Institutions, Hospitals & Clinics, Diagnostic Laboratories, Others)
    • 5.2.6. By Region
    • 5.2.7. By Company (2025)
  • 5.3. Market Map

6. North America Lung Cancer Genomic Testing Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Component
    • 6.2.2. By Technology
    • 6.2.3. By Panel Type
    • 6.2.4. By Sample Type
    • 6.2.5. By End User
    • 6.2.6. By Country
  • 6.3. North America: Country Analysis
    • 6.3.1. United States Lung Cancer Genomic Testing Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Component
        • 6.3.1.2.2. By Technology
        • 6.3.1.2.3. By Panel Type
        • 6.3.1.2.4. By Sample Type
        • 6.3.1.2.5. By End User
    • 6.3.2. Canada Lung Cancer Genomic Testing Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Component
        • 6.3.2.2.2. By Technology
        • 6.3.2.2.3. By Panel Type
        • 6.3.2.2.4. By Sample Type
        • 6.3.2.2.5. By End User
    • 6.3.3. Mexico Lung Cancer Genomic Testing Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Component
        • 6.3.3.2.2. By Technology
        • 6.3.3.2.3. By Panel Type
        • 6.3.3.2.4. By Sample Type
        • 6.3.3.2.5. By End User

7. Europe Lung Cancer Genomic Testing Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Component
    • 7.2.2. By Technology
    • 7.2.3. By Panel Type
    • 7.2.4. By Sample Type
    • 7.2.5. By End User
    • 7.2.6. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. Germany Lung Cancer Genomic Testing Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Component
        • 7.3.1.2.2. By Technology
        • 7.3.1.2.3. By Panel Type
        • 7.3.1.2.4. By Sample Type
        • 7.3.1.2.5. By End User
    • 7.3.2. France Lung Cancer Genomic Testing Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Component
        • 7.3.2.2.2. By Technology
        • 7.3.2.2.3. By Panel Type
        • 7.3.2.2.4. By Sample Type
        • 7.3.2.2.5. By End User
    • 7.3.3. United Kingdom Lung Cancer Genomic Testing Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Component
        • 7.3.3.2.2. By Technology
        • 7.3.3.2.3. By Panel Type
        • 7.3.3.2.4. By Sample Type
        • 7.3.3.2.5. By End User
    • 7.3.4. Italy Lung Cancer Genomic Testing Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Component
        • 7.3.4.2.2. By Technology
        • 7.3.4.2.3. By Panel Type
        • 7.3.4.2.4. By Sample Type
        • 7.3.4.2.5. By End User
    • 7.3.5. Spain Lung Cancer Genomic Testing Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Component
        • 7.3.5.2.2. By Technology
        • 7.3.5.2.3. By Panel Type
        • 7.3.5.2.4. By Sample Type
        • 7.3.5.2.5. By End User

8. Asia Pacific Lung Cancer Genomic Testing Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Component
    • 8.2.2. By Technology
    • 8.2.3. By Panel Type
    • 8.2.4. By Sample Type
    • 8.2.5. By End User
    • 8.2.6. By Country
  • 8.3. Asia Pacific: Country Analysis
    • 8.3.1. China Lung Cancer Genomic Testing Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Component
        • 8.3.1.2.2. By Technology
        • 8.3.1.2.3. By Panel Type
        • 8.3.1.2.4. By Sample Type
        • 8.3.1.2.5. By End User
    • 8.3.2. India Lung Cancer Genomic Testing Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Component
        • 8.3.2.2.2. By Technology
        • 8.3.2.2.3. By Panel Type
        • 8.3.2.2.4. By Sample Type
        • 8.3.2.2.5. By End User
    • 8.3.3. Japan Lung Cancer Genomic Testing Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Component
        • 8.3.3.2.2. By Technology
        • 8.3.3.2.3. By Panel Type
        • 8.3.3.2.4. By Sample Type
        • 8.3.3.2.5. By End User
    • 8.3.4. South Korea Lung Cancer Genomic Testing Market Outlook
      • 8.3.4.1. Market Size & Forecast
        • 8.3.4.1.1. By Value
      • 8.3.4.2. Market Share & Forecast
        • 8.3.4.2.1. By Component
        • 8.3.4.2.2. By Technology
        • 8.3.4.2.3. By Panel Type
        • 8.3.4.2.4. By Sample Type
        • 8.3.4.2.5. By End User
    • 8.3.5. Australia Lung Cancer Genomic Testing Market Outlook
      • 8.3.5.1. Market Size & Forecast
        • 8.3.5.1.1. By Value
      • 8.3.5.2. Market Share & Forecast
        • 8.3.5.2.1. By Component
        • 8.3.5.2.2. By Technology
        • 8.3.5.2.3. By Panel Type
        • 8.3.5.2.4. By Sample Type
        • 8.3.5.2.5. By End User

9. Middle East & Africa Lung Cancer Genomic Testing Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Component
    • 9.2.2. By Technology
    • 9.2.3. By Panel Type
    • 9.2.4. By Sample Type
    • 9.2.5. By End User
    • 9.2.6. By Country
  • 9.3. Middle East & Africa: Country Analysis
    • 9.3.1. Saudi Arabia Lung Cancer Genomic Testing Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Component
        • 9.3.1.2.2. By Technology
        • 9.3.1.2.3. By Panel Type
        • 9.3.1.2.4. By Sample Type
        • 9.3.1.2.5. By End User
    • 9.3.2. UAE Lung Cancer Genomic Testing Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Component
        • 9.3.2.2.2. By Technology
        • 9.3.2.2.3. By Panel Type
        • 9.3.2.2.4. By Sample Type
        • 9.3.2.2.5. By End User
    • 9.3.3. South Africa Lung Cancer Genomic Testing Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Component
        • 9.3.3.2.2. By Technology
        • 9.3.3.2.3. By Panel Type
        • 9.3.3.2.4. By Sample Type
        • 9.3.3.2.5. By End User

10. South America Lung Cancer Genomic Testing Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Component
    • 10.2.2. By Technology
    • 10.2.3. By Panel Type
    • 10.2.4. By Sample Type
    • 10.2.5. By End User
    • 10.2.6. By Country
  • 10.3. South America: Country Analysis
    • 10.3.1. Brazil Lung Cancer Genomic Testing Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Component
        • 10.3.1.2.2. By Technology
        • 10.3.1.2.3. By Panel Type
        • 10.3.1.2.4. By Sample Type
        • 10.3.1.2.5. By End User
    • 10.3.2. Colombia Lung Cancer Genomic Testing Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Component
        • 10.3.2.2.2. By Technology
        • 10.3.2.2.3. By Panel Type
        • 10.3.2.2.4. By Sample Type
        • 10.3.2.2.5. By End User
    • 10.3.3. Argentina Lung Cancer Genomic Testing Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Component
        • 10.3.3.2.2. By Technology
        • 10.3.3.2.3. By Panel Type
        • 10.3.3.2.4. By Sample Type
        • 10.3.3.2.5. By End User

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Merger & Acquisition (If Any)
  • 12.2. Product Launches (If Any)
  • 12.3. Recent Developments

13. Global Lung Cancer Genomic Testing Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Products

15. Competitive Landscape

  • 15.1. QIAGEN NV
    • 15.1.1. Business Overview
    • 15.1.2. Products & Services
    • 15.1.3. Recent Developments
    • 15.1.4. Key Personnel
    • 15.1.5. SWOT Analysis
  • 15.2. Agilent Technologies Inc.
  • 15.3. Thermo Fisher Scientific Inc.
  • 15.4. Quest Diagnostics Incorporated
  • 15.5. Laboratory Corporation of America Holdings
  • 15.6. CENTOGENE N.V.
  • 15.7. BGI Genomics Co. Ltd.
  • 15.8. CeGaT GmbH
  • 15.9. Illumina Inc.
  • 15.10. F. Hoffmann-La Roche Ltd

16. Strategic Recommendations

17. About Us & Disclaimer